John Mascarenhas
Clinical trials sponsored by John Mascarenhas, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can an arthritis drug tame a rare bone marrow cancer? Results expected Oct 2026 (estimated)
-
Can a menin inhibitor tame myelofibrosis when standard drugs fall short?
Disease control Not yet recruitingThis trial investigates whether revumenib, a menin inhibitor, can safely and effectively treat myelofibrosis, a type of bone marrow cancer. The study first tests revumenib alone in patients who have already tried a JAK inhibitor, then tests it in combination with a JAK inhibitor.…
Phase 1/2 • Sponsor: John Mascarenhas • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New drug combo aims to shrink spleen in Hard-to-Treat myelofibrosis
Disease control Not yet recruitingThis phase II trial tests two oral drugs, selinexor and pacritinib, in 26 adults with myelofibrosis who have anemia and low platelets and have not taken JAK inhibitors before. The main goal is to see if the combination can shrink the spleen by at least 35%. The study also tracks …
Phase 2 • Sponsor: John Mascarenhas • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC